Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

類似資料

• Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
  著者:: Hopkins, Ashley M., 等
  出版事項: (2019)
• Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
  著者:: Hopkins, Ashley M., 等
  出版事項: (2020)
• Afatinib in Non–Small Cell Lung Cancer
  著者:: Wirth, Scott M.
  出版事項: (2015)
• Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
  著者:: Hopkins, Ashley M., 等
  出版事項: (2021)
• Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events
  著者:: Logan, Jessica M., 等
  出版事項: (2021)